| __timestamp | Bio-Techne Corporation | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60716000 | 5496000 |
| Thursday, January 1, 2015 | 119401000 | 9786000 |
| Friday, January 1, 2016 | 140879000 | 6792000 |
| Sunday, January 1, 2017 | 199243000 | 7313000 |
| Monday, January 1, 2018 | 240636000 | 8382000 |
| Tuesday, January 1, 2019 | 264359000 | 10803000 |
| Wednesday, January 1, 2020 | 260583000 | 12944000 |
| Friday, January 1, 2021 | 324951000 | 21967000 |
| Saturday, January 1, 2022 | 372766000 | 32810000 |
| Sunday, January 1, 2023 | 378378000 | 46542000 |
| Monday, January 1, 2024 | 396826000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Bio-Techne Corporation and Xenon Pharmaceuticals Inc. offer a fascinating comparison in this regard. Over the past decade, Bio-Techne has consistently reported higher SG&A expenses, peaking at nearly $400 million in 2024. In contrast, Xenon Pharmaceuticals has maintained a leaner approach, with expenses reaching just under $47 million in 2023. This stark difference highlights Bio-Techne's expansive operational scale compared to Xenon's more focused strategy. However, the absence of data for Xenon in 2024 suggests a potential shift or data reporting gap. As investors and industry analysts look to the future, understanding these cost management strategies will be key to predicting each company's growth trajectory and market positioning.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Bio-Techne Corporation
Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Bio-Techne Corporation and Pharming Group N.V.
Bio-Techne Corporation or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bio-Techne Corporation vs CRISPR Therapeutics AG: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Catalyst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Xencor, Inc.
Breaking Down SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Alkermes plc and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Xenon Pharmaceuticals Inc.